{"id":"NCT02990338","sponsor":"Sanofi","briefTitle":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","officialTitle":"A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-22","primaryCompletion":"2018-11-22","completion":"2023-11-01","firstPosted":"2016-12-13","resultsPosted":"2019-12-06","lastUpdate":"2025-01-17"},"enrollment":307,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Plasma Cell Myeloma"],"interventions":[{"type":"DRUG","name":"Isatuximab","otherNames":["SAR650984","Sarclisa"]},{"type":"DRUG","name":"Pomalidomide","otherNames":["POMALYST IMNOVID"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Pd (pomalidomide + dexamethasone)","type":"ACTIVE_COMPARATOR"},{"label":"IPd (isatuximab + pomalidomide + dexamethasone)","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory multiple myeloma (MM).\n\nSecondary Objectives:\n\n* To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm.\n* To compare the Overall Survival (OS) between the two arms.\n* To evaluate the Time To Progression (TTP) in each arm.\n* To evaluate the PFS in high risk cytogenetic population in each arm.\n* To evaluate the Duration of Response (DOR) in each arm.\n* To evaluate the safety in both treatment arms.\n* To determine the Pharmacokinetic profile of isatuximab in combination with pomalidomide.\n* To evaluate the immunogenicity of isatuximab.\n* To assess disease-specific and generic health-related quality of life (HRQL), disease and treatment-related symptoms, health state utility, and health status.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"From the date of randomization to the date of first documentation of progression, or the date of death from any cause, or initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration: 76.7 weeks)","effectByArm":[{"arm":"Pd (Pomalidomide + Dexamethasone)","deltaMin":6.47,"sd":null},{"arm":"IPd (Isatuximab + Pomalidomide + Dexamethasone)","deltaMin":11.53,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":111,"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Japan","New Zealand","Norway","Poland","Portugal","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31735560","35151415","38299578","36108425","35641409","34800109","33839618","32586908"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":149},"commonTop":["Neutropenia","Upper Respiratory Tract Infection","Diarrhoea","Fatigue","Constipation"]}}